DATE
February 23, 2026
CATEGORY
Blog
SHARE
The rapid expansion of GLP-1 receptor agonists into pediatric obesity care is fundamentally reshaping treatment frameworks, transitioning away from “watchful waiting” toward active, longitudinal management. Experts at the ASPEN 2026 Nutrition Science & Practice Conference highlighted that since the American Academy of Pediatrics released its 2023 guidelines, pharmacotherapy is now recommended for adolescents aged 12 and older as an adjunct to lifestyle interventions. With obesity recognized as a chronic, relapsing-remitting disease that rarely resolves spontaneously, the clinical consensus emphasizes that early intervention is critical to preventing long-term health complications.
The therapeutic landscape has evolved rapidly, with semaglutide and liraglutide demonstrating significant efficacy in reducing Body Mass Index (BMI) among adolescents. Notably, the STEP TEENS trial showed once-weekly semaglutide led to a 16% reduction in BMI over 68 weeks, while the dual agonist tirzepatide has shown even more pronounced effects. However, clinicians caution that these medications must be integrated into a “top-down” strategy that prioritizes overall health. This requires careful titration to avoid over-suppressing hunger and to manage common gastrointestinal side effects and hydration risks.
Beyond physiological management, the digest emphasizes the psychological vigilance required. Experts warn that one in five teenagers with obesity may be at risk for disordered eating. Screening for “atypical anorexia” is essential before initiating therapy. Ultimately, this shift represents a precision medicine framework in pediatric metabolic health, provided practitioners maintain a stigma-free environment and ensure medication serves as a partner to, rather than a replacement for, intensive lifestyle treatment.
To read more, visit Gastroenterology & Endoscopy News